OSTX OS Therapies Incorporated
$1.23▲ +1.65%
Healthcare
Other
After hours
$1.23▲ +0.00%
Oct 27, 5:40 PM ET
Volume 315.9K
Avg Volume (10D) 429.7K
Key Metrics & Fundamentals
Market Cap
$57.57M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.15 - 2.25
% vs 50 MA
-22.49%
% vs 200 MA
-21.53%
RSI-14
28.8
MACD Histogram
-0.0200
Beta (1Y vs SPY)
1.71
Free Cash Flow
-$5.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$8.50M
COGS
–
Operating Exp
$8.58M
Operating Income
-$8.58M
EBIT
-$8.58M
Pretax Income
-$8.63M
Net Income
-$8.63M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million
TMX Newsfile · Oct 19, 2026 8:30 AM ET
Rubenstein Public Relations Named Agency of Record for OS Therapies
GlobeNewswire · Oct 8, 2026 9:22 AM ET
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
TMX Newsfile · Oct 7, 2026 8:30 AM ET
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
TMX Newsfile · Oct 6, 2026 8:30 AM ET
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
TMX Newsfile · Oct 1, 2026 8:30 AM ET
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
TMX Newsfile · Sep 24, 2026 8:22 AM ET
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
TMX Newsfile · Sep 21, 2026 6:30 AM ET
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
TMX Newsfile · Sep 17, 2026 6:00 AM ET
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
TMX Newsfile · Sep 15, 2026 7:46 AM ET
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
TMX Newsfile · Sep 8, 2026 6:00 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See OSTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.